Latest news

• CETP inhibitor class finally dies as Merck abandons anacetrapib

  The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit ... In the interim almost all of those brands have

• Merck & Co's anacetrapib data fails to generate much excitement

  contend in the statin add-on market with PCSK9 inhibitors such as Amgen's Repatha, which showed a larger (15%) risk reduction in the FOURIER trial but are still struggling to ... If Merck does choose to abandon anacetrapib the drug will follow several

• Merck & Co's anacetrapib rescued by positive phase III trial

  cholesterol-lowering drugs now that the PCSK9 inhibitors - Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) - are being used alongside statin therapy. ... CETP inhibitors are designed to increase levels of high-density

• Repatha outcomes data "less than stellar"

  than stellar." Investors are now more cautious on prospects for PCSK9 inhibitors as a result, he suggested in a research note. ... It is one of only two PCSK9 inhibitors on the market, along with Sanofi and Regeneron's Praluent (alirocumab) which is also

• Praluent can stay on market for now, says US court

  Both drugs are PCSK9 inhibitors that have been approved in the US to help patients who cannot meet their cholesterol targets with existing therapy, such as statin drugs, or who have ... Praluent was approved in the US first, but Amgen has so far won the